Evidence map›Paper›PMID 29176980›Full record

ArticleFrontiers in immunology2017

iRAGu: A Novel Inducible and Reversible Mouse Model for Ubiquitous Recombinase Activity.

Marie Bonnet, Leonor Morais Sarmento, Ana C Martins, Daniel Sobral, Joana Silva, Jocelyne Demengeot

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Marie BonnetInstituto Gulbenkian de Ciência, Oeiras, Portugal.
Leonor Morais SarmentoInstituto Gulbenkian de Ciência, Oeiras, Portugal.
Ana C MartinsInstituto Gulbenkian de Ciência, Oeiras, Portugal.
Daniel SobralInstituto Gulbenkian de Ciência, Oeiras, Portugal.
Joana SilvaInstituto Gulbenkian de Ciência, Oeiras, Portugal.
Jocelyne DemengeotInstituto Gulbenkian de Ciência, Oeiras, Portugal.
Instituto Gulbenkian de Ciência · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Developing lymphocytes express the recombination activating genes (RAGs) 1 and 2 products that form a site specific recombinase complex (RAG), introducing double strand DNA breaks (DSBs) at recombination signal sequences (RSSs) flanking the V, D, and J gene segments in the antigen receptor loci. The subsequent steps in the reaction consist in the ligation of DSBs by ubiquitous enzymes of the non-homologous end joining DNA repair pathway. This mutagenesis process is responsible for the generation of the very large clonal diversity of T and B lymphocytes, itself allowing the recognition of a virtually open-ended antigenic universe. Sequences resembling RSS are found at high frequency all over the genome, and involved in RAG mediated illegitimate recombination and translocations. Hence, natural and induced ectopic activity of RAG is a threat to the genome only recently underscored. Here, we report and characterize a novel mouse transgenic system for which ubiquitous expression of the recombinase is inducible. In this system, the RAG1 protein is constitutively expressed and functional, while the RAG2 protein, coupled to the estrogen receptor, becomes functionally active upon 4-hydroxytamoxifen (TAM) administration. We describe two transgenic lines. The first one, when introgressed into an endogenous Rag2

Indexed as

4-hydroxytamoxifen inductionestrogen receptorlymphocyte developmentrecombination activating genetransgenic mouse modelV(D)J recombination

Identifiers

PMID29176980
PMCPMC5686385
OpenAlexW2767372027

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.